Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(3.19)
# 1,073
Out of 5,241 analysts
121
Total ratings
40.8%
Success rate
3.33%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Reiterates: Buy | $40 | $11.70 | +241.88% | 5 | May 14, 2026 | |
| MNKD MannKind | Maintains: Buy | $8 → $10 | $2.99 | +234.45% | 10 | May 7, 2026 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $21 | $13.43 | +56.37% | 5 | May 6, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Reiterates: Buy | $11 | $6.69 | +64.42% | 7 | May 4, 2026 | |
| ACHV Achieve Life Sciences | Reiterates: Buy | $12 | $4.77 | +151.57% | 4 | Apr 16, 2026 | |
| SINT Sintx Technologies | Initiates: Buy | $10 | $2.23 | +348.43% | 1 | Apr 13, 2026 | |
| RANI Rani Therapeutics Holdings | Reiterates: Buy | $11 | $0.9723 | +1,031.34% | 5 | Mar 27, 2026 | |
| DERM Journey Medical | Reiterates: Buy | $13 | $6.25 | +108.00% | 3 | Mar 26, 2026 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $60 | $33.65 | +78.31% | 9 | Mar 20, 2026 | |
| PTHS Pelthos Therapeutics | Reiterates: Buy | $60 | $26.15 | +129.45% | 2 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $6.66 | +335.44% | 3 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $6.01 | +66.39% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.73 | +174.84% | 5 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.28 | +603.13% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $13.45 | +48.70% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $13 | $7.91 | +64.35% | 5 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $0.8594 | +598.16% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.46 | +447.95% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.76 | +354.55% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.04 | +861.54% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $79.34 | +52.51% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.70 | +215.79% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.41 | +190.46% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $10.43 | +149.28% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.7814 | +539.88% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $1.61 | +12,322.36% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $8.13 | +96.80% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $5.98 | +7,508.70% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $21.89 | +169.53% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $229.55 | -21.59% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.12 | +10,277.36% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $37.19 | -13.96% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $0.9335 | +2,356,622.01% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 → $315 | $9.60 | +3,181.25% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $8.49 | +488.93% | 1 | Jul 12, 2018 |
Omeros
May 14, 2026
Reiterates: Buy
Price Target: $40
Current: $11.70
Upside: +241.88%
MannKind
May 7, 2026
Maintains: Buy
Price Target: $8 → $10
Current: $2.99
Upside: +234.45%
Trevi Therapeutics
May 6, 2026
Reiterates: Buy
Price Target: $21
Current: $13.43
Upside: +56.37%
Eupraxia Pharmaceuticals
May 4, 2026
Reiterates: Buy
Price Target: $11
Current: $6.69
Upside: +64.42%
Achieve Life Sciences
Apr 16, 2026
Reiterates: Buy
Price Target: $12
Current: $4.77
Upside: +151.57%
Sintx Technologies
Apr 13, 2026
Initiates: Buy
Price Target: $10
Current: $2.23
Upside: +348.43%
Rani Therapeutics Holdings
Mar 27, 2026
Reiterates: Buy
Price Target: $11
Current: $0.9723
Upside: +1,031.34%
Journey Medical
Mar 26, 2026
Reiterates: Buy
Price Target: $13
Current: $6.25
Upside: +108.00%
Collegium Pharmaceutical
Mar 20, 2026
Reiterates: Buy
Price Target: $60
Current: $33.65
Upside: +78.31%
Pelthos Therapeutics
Mar 19, 2026
Reiterates: Buy
Price Target: $60
Current: $26.15
Upside: +129.45%
Mar 11, 2026
Reiterates: Buy
Price Target: $29
Current: $6.66
Upside: +335.44%
Mar 2, 2026
Reiterates: Buy
Price Target: $10
Current: $6.01
Upside: +66.39%
Feb 11, 2026
Reiterates: Buy
Price Target: $13
Current: $4.73
Upside: +174.84%
Feb 10, 2026
Reiterates: Buy
Price Target: $9
Current: $1.28
Upside: +603.13%
Feb 10, 2026
Reiterates: Buy
Price Target: $20
Current: $13.45
Upside: +48.70%
Jan 23, 2026
Maintains: Buy
Price Target: $18 → $13
Current: $7.91
Upside: +64.35%
Jan 9, 2026
Reiterates: Buy
Price Target: $6
Current: $0.8594
Upside: +598.16%
Jan 6, 2026
Reiterates: Buy
Price Target: $8
Current: $1.46
Upside: +447.95%
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $1.76
Upside: +354.55%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.04
Upside: +861.54%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $79.34
Upside: +52.51%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $5.70
Upside: +215.79%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.41
Upside: +190.46%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $10.43
Upside: +149.28%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.7814
Upside: +539.88%
Nov 14, 2024
Initiates: Buy
Price Target: $200
Current: $1.61
Upside: +12,322.36%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $8.13
Upside: +96.80%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $5.98
Upside: +7,508.70%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $21.89
Upside: +169.53%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $229.55
Upside: -21.59%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.12
Upside: +10,277.36%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $37.19
Upside: -13.96%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $0.9335
Upside: +2,356,622.01%
Mar 5, 2020
Reiterates: Overweight
Price Target: $405 → $315
Current: $9.60
Upside: +3,181.25%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $8.49
Upside: +488.93%